Kernicterus‑related encephalopathy - Causes, Treatment & When to See a Doctor

```html

What is Kernicterus‑Related Encephalopathy?

Kernicterus‑related encephalopathy is a form of brain injury that occurs when excessively high levels of unconjugated (indirect) bilirubin cross the newborn’s blood‑brain barrier and deposit in regions of the brain that control movement, hearing, and vision. The term “kernicterus” refers to the yellow‑brown staining of the basal ganglia and brainstem nuclei that can be seen on autopsy, while “encephalopathy” describes the functional neurological impairment caused by that bilirubin toxicity.

In healthy infants, bilirubin—a by‑product of the breakdown of red blood cells—is normally processed by the liver and eliminated in the stool. When bilirubin accumulates faster than the liver can clear it, serum levels rise (hyperbilirubinemia). If the free, unbound fraction of bilirubin exceeds the binding capacity of albumin, it becomes neurotoxic. The developing brain of a newborn is especially vulnerable because the blood‑brain barrier is immature.

Early recognition is crucial: once bilirubin has entered the brain, damage can be permanent, leading to cerebral palsy, sensorineural hearing loss, vision problems, and cognitive deficits.

Common Causes

Several conditions can precipitate the severe hyperbilirubinemia that leads to kernicterus‑related encephalopathy. The most frequent are listed below.

• Hemolytic disease of the newborn (HDN) – maternal‑fetal blood group incompatibility (e.g., Rh or ABO).
• Breast‑feeding jaundice – inadequate milk intake during the first days of life, leading to dehydration and reduced bilirubin excretion.
• Breast‑feeding jaundice (late onset) – substances in breast milk that inhibit bilirubin conjugation (e.g., β‑glucuronidase).
• G6PD deficiency – an inherited enzyme defect causing accelerated red‑cell breakdown.
• Hereditary spherocytosis or other red‑cell membrane disorders – increase hemolysis.
• Crigler‑Najjar syndrome type I – absent UDP‑glucuronosyltransferase activity, preventing bilirubin conjugation.
• Gilbert syndrome (severe neonatal presentation) – reduced enzyme activity, usually mild but can exacerbate other risk factors.
• Sepsis or severe infection – impairs liver function and can increase hemolysis.
• Prematurity – immature liver enzymes and a more permeable blood‑brain barrier.
• Use of certain medications – e.g., sulfonamides, certain antibiotics, or drugs that displace bilirubin from albumin.

Associated Symptoms

The clinical picture evolves as bilirubin levels rise and neurotoxicity progresses. Early signs are often subtle, making vigilant observation essential.

• Yellow coloration of the skin and sclera (jaundice) persisting beyond the first week of life.
• Poor feeding or difficulty sucking.
• Lethargy or excessive sleepiness.
• Irritability or inconsolable crying.
• High‑pitched “cry” that may be a sign of auditory pathway involvement.
• Hypotonia (floppiness) or, later, hypertonia (spasticity) especially in the limbs.
• Abnormal eye movements (e.g., nystagmus) and delayed visual tracking.
• Muscle rigidity or “opisthotonus” (arched back) in severe cases.
• Seizures, which may be focal or generalized.
• Feeding difficulties that can lead to weight loss and dehydration.

When to See a Doctor

Because kernicterus can develop rapidly, parents and caregivers should seek medical attention promptly if any of the following occur:

• Jaundice that spreads to the abdomen, arms, or legs, or that deepens in color.
• Newborn is sleeping more than usual, difficult to rouse, or shows decreased responsiveness.
• Persistent crying that cannot be soothed.
• Feeding problems: refusing feeds, taking < 60 mL per feeding, or losing weight.
• Any sign of seizure activity (staring, jerking, stiffening).
• Muscle stiffness, abnormal posturing, or loss of muscle tone.
• Family history of hemolytic disease, G6PD deficiency, or liver enzyme disorders.

In the first 24‑48 hours after birth, a bilirubin level > 12 mg/dL in a term infant (or lower thresholds in pre‑term infants) warrants urgent evaluation.

Diagnosis

Diagnosis combines clinical assessment with laboratory and imaging studies.

1. Physical examination

The clinician assesses the extent of jaundice (using the Kramer scale), checks for neurological signs (tone, reflexes, eye movements), and looks for underlying causes (e.g., hepatomegaly, splenomegaly).

2. Serum bilirubin measurement

• Total serum bilirubin (TSB) – determines severity. • Direct (conjugated) vs. indirect (unconjugated) bilirubin – kernicterus is associated with markedly elevated indirect bilirubin.

3. Laboratory work‑up for underlying etiology

• Complete blood count (CBC) and reticulocyte count – to detect hemolysis.
• Blood type and Coombs test – to rule out alloimmune hemolysis.
• G6PD assay, peripheral smear, enzyme studies for hereditary spherocytosis.
• Liver function tests (AST, ALT, alkaline phosphatase, GGT).

4. Imaging

• Transcranial ultrasound – can show basal ganglia echogenicity in severe cases.
• Brain MRI – the gold standard for detecting bilirubin‑induced changes (hyperintensity in globus pallidus).

5. Auditory Brainstem Response (ABR) testing

Early screening for sensorineural hearing loss, a common sequel of kernicterus.

6. Neurodevelopmental assessment

Baseline evaluation by a pediatric neurologist or developmental specialist to monitor long‑term outcomes.

Treatment Options

Management focuses on rapidly lowering serum bilirubin, preventing further neurotoxicity, and supporting the infant’s overall health.

Phototherapy

• First‑line treatment for most cases of severe jaundice. Blue‑light (≈460 nm) converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Intensity: high‑intensity (≥30 µW/cm²/nm) for bilirubin > 20 mg/dL in term infants or lower thresholds in pre‑term infants.
• Continuous monitoring of TSB levels every 4‑6 hours.

Exchange Transfusion

• Indicated when bilirubin exceeds the phototherapy ceiling (e.g., > 25 mg/dL in term infants) or if encephalopathic signs appear despite phototherapy.
• Rapidly replaces the infant’s plasma with donor blood, lowering bilirubin and reducing circulating antibodies in hemolytic disease.
• Risks include electrolyte disturbances, infections, and blood‑type incompatibility; therefore, performed in a NICU with experienced staff.

Intravenous Immunoglobulin (IVIG)

• Useful in immune‑mediated hemolysis (e.g., Rh incompatibility) when exchange transfusion is not immediately available.
• Doses of 1 g/kg over 2‑4 hours can reduce the need for exchange in up to 30 % of cases (American Academy of Pediatrics guidelines).

Supportive Care

• Ensuring adequate hydration and caloric intake – promote bilirubin excretion via stool.
• Frequent feeding (every 2‑3 hours) or supplemental tube feeds if oral intake is insufficient.
• Monitoring electrolytes, blood glucose, and acid‑base status.
• Thermoregulation – maintain neutral thermal environment.

Long‑Term Management

• Early intervention services (physiotherapy, occupational therapy, speech therapy) for motor or developmental delays.
• Regular audiology and ophthalmology follow‑up.
• Neurodevelopmental assessments at 6 months, 12 months, and yearly thereafter.

Prevention Tips

Most cases of kernicterus are preventable with early detection and treatment of hyperbilirubinemia.

• Prenatal care – Rh immunoglobulin (RhoGAM) for Rh‑negative mothers; screening for G6PD deficiency in at‑risk populations.
• Early post‑natal bilirubin screening – Measure TSB or use transcutaneous bilirubinometry before discharge (ideally at 24 h for term infants, 48 h for pre‑term).
• Educate parents – Explain how to recognize jaundice and the importance of feeding frequently.
• Encourage breastfeeding – Provide lactation support to prevent breast‑feeding jaundice; consider supplemental feeds if infant is not gaining weight.
• Avoid medications that displace bilirubin – Discuss any drug use with the pediatrician, especially sulfonamides, aspirin, or certain antibiotics.
• Follow discharge follow‑up schedule – Typically a pediatric visit within 48 hours after birth for term infants, earlier for those with risk factors.
• Monitor high‑risk infants closely – Premature babies, those with known hemolytic disease, or with a family history of bilirubin metabolism disorders need serial bilirubin checks.

Emergency Warning Signs

Key Take‑aways

• Kernicterus‑related encephalopathy is a preventable, yet potentially devastating, form of brain injury caused by extreme unconjugated hyperbilirubinemia.
• Early identification of jaundice, timely bilirubin measurement, and prompt treatment with phototherapy or exchange transfusion are the cornerstones of prevention.
• Parents should be educated about feeding adequacy, signs of worsening jaundice, and when to seek urgent care.
• Long‑term follow‑up is essential because even with successful treatment, children may develop hearing loss, visual deficits, or motor abnormalities.

For more detailed guidance, consult reputable sources such as the Mayo Clinic, CDC, NIH, and the World Health Organization. If you suspect kernicterus in your infant, do not wait—seek immediate medical evaluation.

```